Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction

European Journal of Pharmacology

Volumn 640, Issue 1-3, 2010, Pages 112-116

  Yue Chun, Li ^a   Li Sha, Ge ^a   Peng Lin, Yang ^a   Ji Fei, Tang ^a   Jia Feng, Lin ^a   Peng, Chen ^a   Xue Qiang, Guan ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

4 Hydroxy 2 nonenal; Carvedilol; Viral myocarditis

Indexed keywords

4 HYDROXYNONENAL; CARVEDILOL; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; METOPROLOL; PEROXIDE; SUPEROXIDE DISMUTASE; 4-HYDROXY-2-NONENAL; ADRENERGIC RECEPTOR BLOCKING AGENT; ALDEHYDE; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIOXIDANT ACTIVITY; ARTICLE; COXSACKIE VIRUS B; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME ACTIVITY; HEART FUNCTION; HEART MUSCLE; HISTOPATHOLOGY; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; VIRUS MYOCARDITIS; ANIMAL; BAGG ALBINO MOUSE; BODY WEIGHT; DRUG EFFECTS; ELECTROCARDIOGRAPHY; ENTEROVIRUS; HEART; HEMODYNAMICS; METABOLISM; MYOCARDITIS; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; VIROLOGY; VIRUS LOAD;

ADRENERGIC ANTAGONISTS; ALDEHYDES; ANIMALS; BODY WEIGHT; CARBAZOLES; ELECTROCARDIOGRAPHY; ENTEROVIRUS; GLUTATHIONE PEROXIDASE; HEART; HEMODYNAMICS; MALE; MALONDIALDEHYDE; METOPROLOL; MICE; MICE, INBRED BALB C; MYOCARDITIS; MYOCARDIUM; ORGAN SIZE; OXIDATIVE STRESS; PROPANOLAMINES; SUPEROXIDE DISMUTASE; SURVIVAL RATE; TIME FACTORS; VIRAL LOAD;

EID: 77953811576     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.04.037     Document Type: Article

References (33)

1. Amin J.K., Xiao L., Pimental D.R., Pagano P.J., Singh K., Sawyer D.B., Colucci W.S. Reactive oxygen species mediate α-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J. Mol. Cell. Cardiol. 2001, 33:131-139.
2. Bhatnagar A. Electrophysiological effects of 4-hydroxynonenal, an aldehydic product of lipid peroxidation, on isolated rat ventricular myocytes. Circ. Res. 1995, 76:293-304.
3. Dulin B., Abraham W.T. Pharmacology of carvedilol. Am. J. Cardiol. 2004, 93:3-6.
4. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11:81-128.
5. Feuerstein G., Liu G.L., Yue T.L., Cheng H.Y., Hieble J.P., Arch J.R., Ruffolo R.R., Ma X.L. Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. Eur. J. Pharmacol. 1998, 351:341-350.
6. Feuerstein G., Shusterman N.H., Ruffolo R.R. Carvedilol update IV: prevention of oxidative stress, cardiac remodeling and progression congestive heart failure. Drugs Today 1997, 33:453-473.
7. Flesch M., Maack C., Cremers B., Bäumer A.T., Südkamp M., Böhm M. Effect of β-adrenoceptor antagonist on free radical-induced cardiac contractile dysfunction. Circulation 1999, 100:346-353.
8. Haenen G.R., Plug H.J., Vermeulen N.P., Timmerman H., Bast A. Contribution of 4-hydroxy-2, 3-trans-nonenal to the reduction of β-adrenoceptor function in the heart by oxidative stress. Life Sci. 1989, 45:71-76.
9. Hayashi T., Ijiri Y., Toko H., Shimomura H., Okabe M., Terasaki F., Kitaura Y., Kawamura K. Increased digitalis-like immunoreactive substances in patients with hypertrophiccardiomyopathy. Eur. Heart J. 2000, 21:296-305.
10. Henke A., Wagner E., Whitton J.L., Zell R., Stelzner A. Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization. J. Virol. 1998, 72:8327-8331.
11. Henke A., Zell R., Stelzner A. DNA vaccine-mediated immune responses in Coxsackie virus B3-infected mice. Antivir. Res. 2001, 49:49-54.
12. Hiraoka Y., Kishimoto C., Takada H., Kurokawa M., Ochiai H., Shiraki K., Sasayama S. Role of oxygen derived free radicals in the pathogenesis of coxsackievirus B3 myocarditis in mice. Cardiovasc. Res. 1993, 27:957-961.
13. Hiraoka Y., Kishimoto C., Takada H., Suzaki N., Shiraki K. Effects of granulocyte colony-stimulating factor upon coxsackievirus B3 myocarditis in mice. Eur. Heart J. 1995, 16:1900-1906.
14. Kim J.M., Lim B.K., Ho S.H., Yun S.H., Shin J.O., Park E.M., Kim D.K., Kim S., Jeon E.S. TNFR-Fc fusion protein expressed by in vivo electroporation improves survival rates and myocardial injury in coxsackievirus induced murine myocarditis. Biochem. Biophys. Res. Commun. 2006, 344:765-771.
15. Liu C., Chen J., Liu K. Immunosuppressive treatment for inflammatory cardiomyopathy: meta-analysis of randomized controlled trials. Int. Heart J. 2005, 46:113-122.
16. Magsio C.H., Hamouda W., Bapna V., Ghanim H., Abu-Reish I.A., Aljada A., Dandona P. Nadolol inhibits reactive oxygen species generation by leukocytes and linoleic acid oxidation. Am. J. Cardiol. 2000, 86:443-448.
17. Matsuo T., Mori H., Nishimura Y., Maeda T., Nakagawa J.I., Obashi A. Quantification of Immunohistochemistry using an image analyser: correlation with hormone concentrations in pituitary adenomas. Histochem. J. 1995, 27:989-996.
18. Natarajan P., Johnson J.E. Molecular packing in virus crystals:geometry, chemistry, and biology. J. Struct. Biol. 1998, 121:295-305.
19. Nishio R., Shioi T., Sasayama S., Matsumori A. Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J. Am. Coll. Cardilol. 2003, 41:340-345.
20. Obata T., Yamanaka Y. Cardiac microdialysis of salicylic acid: OH generation on nonenzymatic oxidation by norepinephrine in rat heart. Biochem. Pharmacol. 1997, 53:1375-1378.
21. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure, US Carvediol Heart Failure Study Group. N Engl J. Med. 1996, 334:1349-1355.
22. Pauschinger M., Doerner A., Kuehl U., Schwimmbeck P.L., Poller W., Kandolf R., Schultheiss H.P. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 1999, 99:889-895.
23. Pauschinger M., Rutschow S., Chandrasekharan K., Westermann D., Weitz A., Peter S.L., Zeichhardt H., Poller W., Noutsias M., Li J., Schultheiss H.P., Tschope C. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1β and MMP-8 expression and a modulated immune response. Eur. J. Heart Fail. 2005, 7:444-452.
24. Qin F., Rounds N.K., Mao W., Kawai K., Liang C.S. Antioxidant vitamins prevent cardiomyocyte apoptosis produced by norepinephrine infusion in ferrets. Cardiovasc. Res. 2001, 51:736-748.
25. See D.M., Tilles J.G. Occurrence of coxsackievirus hepatitis in baby rabbits and protection by a formalin-inactivated polyvalent vaccine. Proc. Soc. Exp. Biol. Med. 1997, 216:52-56.
26. Seong I.W., Choe S.C., Jeon E.S. Fulminant coxsackieviral myocarditis. N Engl J. Med. 2001, 345:379.
27. Singal P.K., Beamish R.E., Dhalla N.S. Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Adv. Exp. Med. Biol. 1983, 161:391-401.
28. Singh N., Dhalla A.K., Seneviratne C., Singal P.K. Oxidative stress and heart failure. Mol. Cell. Biochem. 1995, 147:77-81.
29. Sponer G., Bartsch W., Strein K., Müller-Beckmann B., Böhm E. Pharmacological profile of carvedilol as a β-blocking agent with vasodilating and hypotensive properties. J. Cardiovasc. Pharmacol. 1987, 9:317-327.
30. Takada H., Kishimoto C., Hiraoka Y. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model. Antiviral and anti-inflammatory effects. Circulation 1995, 92:1604-1611.
31. Wei S., Chow L.T., Sanderson J.E. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J. Am. Coll. Cardiol. 2000, 36:276-281.
32. Yue-Chun L., Li-Sha G., Jiang-Hua R., Peng-Lin Y., Jia-Feng L., Ji-Fei T., Peng C., Zhan-Qiu Y. Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. J. Cardiovasc. Pharmacol. 2008, 51:92-98.
33. Zarkovic N. 4-Hydroxynonenal as a bioactive marker of pathophysiological processes. Mol. Aspects Med. 2003, 24:281-291.